Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: Clinical and drug delivery perspectives

Expert Opinion on Drug Delivery

Volumn 13, Issue 1, 2016, Pages 7-22

  Sugianto, Tiffanie Daisy ^a   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

combination antibiotics; inhaled antibiotics; non cystic fibrosis bronchhiectasis; Pseudomonas aeruginosa; respiratory tract infections; sustained release antibiotics

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTIONS; BRONCHIECTASIS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG DELIVERY SYSTEM; HUMAN; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHIECTASIS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84955208340     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1078309     Document Type: Review

References (98)

1. McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188 (6): 647-56
2. Siekmeier R, Hofmann T, Scheuch G. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv Exp Med Biol 2015; 839: 13-24
3. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55 (1): 27-34
4. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12 (4): 205-9
5. Rubin BK, Williams RW. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. Respiration 2014; 88: 177-84
6. Mirsaeidi M, Hadid W, Ericsoussi B, et al. Non-Tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013; 17 (11): e1000-e04
7. Chalmers JD, Smith MP, McHugh BJ, et al. Short-And long-Term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186 (7): 657-65
8. Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Exp Opin Drug Deliv 2014; 24 (2): 169-81
9. Xiong MH, Bao Y, Yang XZ, et al. Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev 2014; 78: 63-76
10. Weers J. Inhaled antimicrobial therapy-Barriers to effective treatment. Adv Drug Deliv Rev 2015; 85: 24-43
11. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-cystic fibrosis bronchiectasis. Thorax 2010; 65 (Suppl 1): i1-i58
12. McCullough AR, Tunney MM, Quittner AL, et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014; 14: 107
13. Respiratory Expert Group. Therapeutic Guidelines: Respiratory. 5th edition. Therapeutic Guidelines Limited, Melbourne; 2015
14. Antibiotic Expert Group. Therapeutic guidelines: Antibiotics. 5th edition. Therapeutic Guidelines Limited, Melbourne; 2014
15. Cipolla D, Chan HK. Inhaled antibiotics to treat lung infection. Pharm Pat Anal 2013; 2 (5): 647-63
16. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 2013; 68 (9): 812-17
17. Weers J, Tarara T. The PulmoSphere platform for pulmonary drug delivery. Ther Deliv 2014; 5 (3): 277-95
18. Weers JG, Bell J, Chan HK, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 2010; 23 (Suppl 2): S5-23
19. Weers J, Ung K, Le J, et al. Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subjects inhalation maneuver. J Aerosol Med Pulm Drug Deliv 2013; 26 (1): 56-68
20. Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013; 33 (6): 419-27
21. Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013; 35 (10): 1571-81
22. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41 (5): 1107-15
23. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162 (2): 481-5
24. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39 (1): 39-44
25. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189 (8): 975-82
26. Murray MP, Govan JRW, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183 (4): 491-9
27. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999; 93 (7): 476-80
28. Tabernero E, Gil P, Alkiza R, et al. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection. Chest 2014; 145 (Suppl 3): 431A
29. Barker AF, ODonnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2 (9): 738-49
30. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130 (5): 1503-10
31. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review. Eur Respir J 2014; 44 (2): 382-93
32. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2014; 11: CD004197
33. White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106 (3): 356-60
34. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183 (11): 1510-16
35. Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68 (4): 344-50
36. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185 (2): 171-8
37. McCaughey G, McKevitt M, Elborn JS, et al. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 2012; 11 (3): 163-72
38. MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64 (4): 829-36
39. Clinical trial registry and database. Available from: https://clinicaltrials.gov. [Last accessed 27 July 2015]
40. Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006; 28 (6): 1204-10
41. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23 (3): 590-615
42. Wu Q, Shen W, Cheng H, et al. Long-Term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-Analysis. Respirology 2014; 19 (3): 321-9
43. Togami K, Chono S, Morimoto K. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. J Aerosol Med Pulm Drug Deliv 2012; 25 (2): 110-15
44. Moghaddam PH, Ramezani V, Esfandi E, et al. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol 2013; 239: 478-83
45. Togami K, Chono S, Seki T, et al. Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Drug Dev Ind Pharm 2010; 36 (7): 861-6
46. Hickey AJ, Lu D, Ashley ED, et al. Inhaled azithromycin therapy. J Aerosol Med 2006; 19 (1): 54-60
47. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014; 75: 81-91
48. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154 (2): 123-40
49. Willis L, Hayes D Jr, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012; 190 (3): 251-62
50. Cheow WS, Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly (lactic-co-glycolic acid) nanoparticles: Modifications of standard nanoparticle preparation methods. Colloids Surf A 2010; 370 (1): 79-86
51. Misra A, Jinturkar K, Patel D, et al. Recent advances in liposomal dry powder formulations: preparation and evaluation. Exp Opin Drug Deliv 2009; 6 (1): 71-89
52. Gaspar MM, Bakowsky U, Ehrhardt C. Inhaled liposomes-current strategies and future challenges. J Biomed Nanotechnol 2008; 4 (3): 245-57
53. Mugabe C, Azghani AO, Omri A. Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm 2006; 307 (2): 244-50
54. Alipour M, Halwani M, Omri A, et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008; 355 (1-2): 293-8
55. Wallace SJ, Nation RL, Li J, et al. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J Pharm Sci 2013; 102 (5): 1578-87
56. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv 2013; 4 (8): 1047-72
57. Ungaro F, dAngelo I, Miro A, et al. Engineered PLGA nano-And micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012; 64 (9): 1217-35
58. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189 (5): 576-85
59. Poppelwell L, Chalmers JD. Defining severity in non-cystic fibrosis bronchiectasis. Exp Rev Respir Med 2014; 8 (2): 249-62
60. Metersky ML, ODonnell AE. Nebulized colistin for non-cystic fibrosis bronchiectasis: deja vu all over again? Am J Respir Crit Care Med 2014; 189 (10): 1151-2
61. De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013; 68 (7): 695-6
62. Fried LP, Ferrucci L, Darer J, et al. Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. J Gerontol A Biol Sci Med Sci 2004; 59 (3): M255-M63
63. Greally P, Whitaker P, Peckham D. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Med Res Opin 2012; 28 (6): 1059-67
64. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014; 11 (3): 425-34
65. Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13 (6): 692-8
66. Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010; 55 (7): 911-21
67. Alipour M, Suntres ZE. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa. Ther Deliv 2014; 5 (4): 409-27
68. Hoffman LR, DArgenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436 (7054): 1171-5
69. Quittner AL, ODonnell AE, Salathe MA, et al. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015; 70 (1): 12-20
70. Rogers GB, Van Der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68 (8): 731-7
71. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014; 11 (4): 496-503
72. Gonem S, Scadding A, Soares M, et al. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respir Res 2014; 15: 59
73. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010; 193 (6): 356-65
74. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136 (6): 1521-8
75. Martínez-García M-A, de la Rosa Carrillo D, Soler-Cataluña J-J, et al. Prognostic value of bronchiectasis in patients with moderate-To-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (8): 823-31
76. Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141 (2): 461-8
77. Mukker JK, Singh RSP, Derendorf H. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Adv Drug Deliv Rev 2015; 85: 57-64
78. Velkov T, Abdul Rahim N, Zhou Q, et al. Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Adv Drug Deliv Rev 2015; 85: 65-82
79. Hittinger M, Juntke J, Kletting S, et al. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv Drug Deliv Rev 2016; 85: 44-56
80. Tre-Hardy M, Nagant C, El Manssouri N, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010; 54 (10): 4409-15
81. Elkhatib W, Noreddin A. Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. Microb Drug Resist 2014; 20 (6): 575-82
82. Lee SH, Teo J, Heng D, et al. Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. Eur J Pharm Biopharm 2013; 83 (2): 275-84
83. El-Din MA, Palmer LB, el-Tayeb MN, et al. Nebulizer therapy with antibiotics in chronic suppurative lung disease. J Aerosol Med 1994; 7 (4): 345-50
84. Aquino RP, Prota L, Auriemma G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm 2012; 426 (1-2): 100-7
85. Ungaro F, dAngelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012; 157 (1): 149-59
86. Beaulac C, Clément-Major S, Hawari J, et al. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996; 40 (3): 665-9
87. Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 1999; 7 (1): 33-41
88. Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013; 57 (6): 2694-704
89. Zhang Y, Wang X, Lin X, et al. High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 2010; 395 (1-2): 205-14
90. Adi H, Young PM, Chan H-K, et al. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 2010; 40 (3): 239-47
91. Arnold MM, Gorman EM, Schieber LJ, et al. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 2007; 121 (1-2): 100-9
92. Ong HX, Traini D, Cipolla D, et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res 2012; 29 (12): 3335-46
93. Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2014; 477: 485-94
94. Adi H, Young PM, Chan HK, et al. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008; 97 (8): 3356-66
95. Adi H, Young PM, Chan HK, et al. Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 2010; 36 (1): 119-26
96. Lee SH, Teo J, Heng D, et al. A novel inhaled multi-pronged attack against respiratory Bacteria. Eur J Pharm Sci 2015; 70: 37-44
97. Park CW, Li X, Vogt FG, et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 2013; 455 (1-2): 374-92
98. Pilcer G, Rosiere R, Traina K, et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 2013; 102 (6): 1836-46